- Home
- GMAB vs HRL Comparison
GMAB vs HRL Comparison
Compare GMAB & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- HRL
- Stock Information
- Founded
- GMAB 1999
- HRL 1891
- Country
- GMAB Denmark
- HRL United States
- Employees
- GMAB N/A
- HRL N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- HRL Meat/Poultry/Fish
- Sector
- GMAB Health Care
- HRL Consumer Staples
- Exchange
- GMAB Nasdaq
- HRL Nasdaq
- Market Cap
- GMAB 15.0B
- HRL 18.2B
- IPO Year
- GMAB N/A
- HRL N/A
- Fundamental
- Price
- GMAB $22.96
- HRL $31.56
- Analyst Decision
- GMAB Buy
- HRL Hold
- Analyst Count
- GMAB 8
- HRL 6
- Target Price
- GMAB $43.00
- HRL $32.67
- AVG Volume (30 Days)
- GMAB 1.0M
- HRL 2.2M
- Earning Date
- GMAB 11-06-2024
- HRL 11-27-2024
- Dividend Yield
- GMAB N/A
- HRL 3.58%
- EPS Growth
- GMAB 19.99
- HRL N/A
- EPS
- GMAB 12.13
- HRL 1.43
- Revenue
- GMAB $2,732,097,558.00
- HRL $11,980,786,000.00
- Revenue This Year
- GMAB $30.45
- HRL N/A
- Revenue Next Year
- GMAB $16.19
- HRL $2.43
- P/E Ratio
- GMAB $18.06
- HRL $22.13
- Revenue Growth
- GMAB 17.19
- HRL N/A
- 52 Week Low
- GMAB $22.52
- HRL $28.51
- 52 Week High
- GMAB $32.89
- HRL $36.86
- Technical
- Relative Strength Index (RSI)
- GMAB 31.19
- HRL 51.33
- Support Level
- GMAB $22.52
- HRL $30.91
- Resistance Level
- GMAB $23.75
- HRL $31.50
- Average True Range (ATR)
- GMAB 0.28
- HRL 0.40
- MACD
- GMAB 0.01
- HRL 0.03
- Stochastic Oscillator
- GMAB 23.40
- HRL 65.42
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and become a branded food company. The firm sells its wares through multiple channels, including US retail (64% of fiscal 2023 sales), US food service (30%), and international (6%). By product, 70% of fiscal 2023 sales were from perishable food and 30% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.